



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Administrative Notice

March 30, 2021

To: Safety Committee of the Federation of Pharmaceutical Manufacturers'
Associations of Japan

Pharmaceutical Safety division, Pharmaceutical Safety and Environmental
Health Bureau, Ministry of Health, Labour and Welfare

Partial Correction to Revision of Precautions

Part of the Revision of Precautions of package inserts notified by PSEHB/PSD 0225 No.1 by the Director of Pharmaceutical Safety Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare has been corrected as follows. The full version of the corrected revision of precautions has been posted in the website page to replace the old version.

*Corrected language is underlined.

Correction	Current	Corrected
Proposed revision for non-pyrine common cold medicine	Use during Pregnancy, Delivery or Lactation This drug should be administered to pregnant women <u>(those within 12 weeks before due date or in their third trimester)</u> or women who may be pregnant only when the potential therapeutic benefits are considered to outweigh the potential risks. (snip)	Use during Pregnancy, Delivery or Lactation This drug should be administered to pregnant women or women who may be pregnant only when the potential therapeutic benefits are considered to outweigh the potential risks. (snip)